Literature DB >> 2690614

In vitro antimicrobial activity and susceptibility testing of ofloxacin. Current status.

P C Fuchs1.   

Abstract

The fluoroquinolone, ofloxacin, exhibits a broad antibacterial spectrum. Based on our data and a review of the literature, ofloxacin inhibited essentially 100 percent of staphylococci, including oxacillin-resistant strains, Haemophilus influenzae, Neisseria spp. and Branhamella catarrhalis. Ninety-five percent of Enterobacteriaceae were susceptible to ofloxacin. Pseudomonas aeruginosa and enterococci were less susceptible: 79 and 63 percent, respectively, were susceptible (minimal inhibitory concentration [MIC], less than or equal to 2.0 micrograms/ml); 15 and 25 percent, respectively, were intermediate (MIC, 4 micrograms/ml); 3 and 6 percent, respectively, were resistant (MIC, more than or equal to 4 micrograms/ml). Clostridium spp., including Clostridium difficile, were resistant to ofloxacin, but other anaerobic species, including the Bacteroides fragilis group (over 90 percent) were either susceptible or intermediate to ofloxacin. Ofloxacin is bactericidal; minimal bactericidal concentrations of ofloxacin rarely exceed the MICs by one doubling concentration. A modest inoculum effect has been observed with ofloxacin: MICs with inocula of 10(7) colony-forming units/ml are often two- to fourfold higher than those with inocula of 5 x 10(5) colony-forming units/ml. Susceptible organisms exposed serially to increasing concentrations of nalidixic acid developed increasing resistance to not only nalidixic acid, but also to all other quinolones, including ofloxacin. Correlations of disk diffusion inhibitory zone diameters using the 5-micrograms ofloxacin disk with ofloxacin MICs have been performed, and the disk diffusion zone diameter breakpoints recommended are: susceptible, greater than or equal to 16 mm; intermediate, 13 to 15 mm; resistant, less than or equal to 12 mm. Quality control parameters also are summarized.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2690614

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

Review 1.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 2.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

3.  Comparative prophylactic efficacies of ciprofloxacin, ofloxacin, cefazolin, and vancomycin in experimental model of staphylococcal wound infection.

Authors:  D S Kernodle; A B Kaiser
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

4.  Susceptibility of anaerobic bacteria isolated from intra-abdominal infections to ofloxacin and interaction of ofloxacin with metronidazole.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.